Cargando…

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice

BACKGROUND & AIMS: The bile acid (BA)-activated farnesoid X receptor (FXR) controls hepatic BA synthesis and cell proliferation via the intestinal hormone fibroblast growth factor 19. Because cystic fibrosis (CF) is associated with intestinal dysbiosis, anomalous BA handling, and biliary cirrhos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikpa, Pauline T., Doktorova, Marcela, Meijsen, Kelly F., Nieuwenhuijze, Natascha D.A., Verkade, Henkjan J., Jonker, Johan W., de Jonge, Hugo R., Bijvelds, Marcel J.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881665/ https://www.ncbi.nlm.nih.gov/pubmed/31470114 http://dx.doi.org/10.1016/j.jcmgh.2019.08.006

Ejemplares similares

Bicarbonate Transport in Cystic Fibrosis and Pancreatitis
por: Angyal, Dora, et al.
Publicado: (2021)

Guanylin and uroguanylin are produced by mouse intestinal epithelial cells of columnar and secretory lineage
por: Ikpa, Pauline T., et al.
Publicado: (2016)

Selective inhibition of intestinal guanosine 3′,5′-cyclic monophosphate signaling by small-molecule protein kinase inhibitors
por: Bijvelds, Marcel J. C., et al.
Publicado: (2018)

Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
por: de Jonge, Hugo R., et al.
Publicado: (2020)

Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia
por: Doktorova, Marcela, et al.
Publicado: (2017)

Alterations of mucosa-attached microbiome and epithelial cell numbers in the cystic fibrosis small intestine with implications for intestinal disease
por: Kelly, Jennifer, et al.
Publicado: (2022)

Cholic Acid Induces a Cftr Dependent Biliary Secretion and Liver Growth Response in Mice
por: Bodewes, Frank A. J. A., et al.
Publicado: (2015)

Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR
por: Bose, Samuel J., et al.
Publicado: (2019)

Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers
por: Ciciriello, Fabiana, et al.
Publicado: (2022)

The role of the gut microbiome in graft fibrosis after pediatric liver transplantation
por: Qin, Tian, et al.
Publicado: (2020)

A Potential Treatment of Congenital Sodium Diarrhea in Patients With Activating GUCY2C Mutations
por: van Vugt, Anke H.M., et al.
Publicado: (2021)

Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
por: Wang, Hong, et al.
Publicado: (2018)

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats
por: Ceulemans, Laurens J., et al.
Publicado: (2017)

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
por: Jiang, Changtao, et al.
Publicado: (2015)

Distal intestinal obstruction syndrome: a diagnostic and therapeutic challenge in cystic fibrosis()()
por: Sandy, Natascha S., et al.
Publicado: (2019)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Intestinal Dysbiosis in Young Cystic Fibrosis Rabbits
por: Liang, Xiubin, et al.
Publicado: (2021)

Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter α-β
por: van de Wiel, Sandra M.W., et al.
Publicado: (2017)

Spontaneous rescue from cystic fibrosis in a mouse model
por: Charizopoulou, Nikoletta, et al.
Publicado: (2006)

Enhanced Alcoholic Liver Disease in Mice with Intestine-specific Farnesoid X Receptor Deficiency
por: Huang, Mingxing, et al.
Publicado: (2020)

Identification of the fructose transporter GLUT5 (SLC2A5) as a novel target of nuclear receptor LXR
por: Zwarts, Irene, et al.
Publicado: (2019)

Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype
por: De Lisle, Robert C, et al.
Publicado: (2010)

Development of the intestinal microbiome in cystic fibrosis in early life
por: Price, Courtney E., et al.
Publicado: (2023)

Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor
por: Tveter, Kevin M, et al.
Publicado: (2020)

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study
por: Erken, Robin, et al.
Publicado: (2021)

Human extrahepatic and intrahepatic cholangiocyte organoids show region-specific differentiation potential and model cystic fibrosis-related bile duct disease
por: Verstegen, Monique M. A., et al.
Publicado: (2020)

Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2020)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
por: Boesjes, Marije, et al.
Publicado: (2014)

Intestinal Obstruction Syndromes in Cystic Fibrosis: Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Constipation
por: van der Doef, Hubert P. J., et al.
Publicado: (2011)

Hypertonic saline releases the attached small intestinal cystic fibrosis mucus
por: Ermund, Anna, et al.
Publicado: (2015)

Cystic Fibrosis
por: Dodge, J A
Publicado: (1997)

Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis
por: Nielsen, Shaun, et al.
Publicado: (2016)

CFTR High Expresser Cells in cystic fibrosis and intestinal diseases
por: Carlos dos Reis, Diego, et al.
Publicado: (2023)

Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice
por: Jiang, Jie, et al.
Publicado: (2022)

The intestinal virome in children with cystic fibrosis differs from healthy controls
por: Coffey, Michael J., et al.
Publicado: (2020)

Intestinal Farnesoid X Receptor Modulates Duodenal Surface Area but Does Not Control Glucose Absorption in Mice
por: Yang, Jiufang, et al.
Publicado: (2023)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Folding–function relationship of the most common cystic fibrosis–causing CFTR conductance mutants
por: van Willigen, Marcel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mhteojpbl6d3dnmlph0oisq8tf